Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia

NCT00006400 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

193

Enrollment

NIH

Sponsor class

Conditions

Hematologic Diseases
Anemia, Sickle Cell

Interventions

DRUG: Hydroxyurea
DRUG: Placebo

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)